A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

PURPOSE: To determine the toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of cediranib administered orally, once daily, continuously in children and adolescents with solid tumors. PATIENTS AND METHODS: Children and adolescents w...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Fox, Elizabeth, Aplenc, Richard, Bagatell, Rochelle, Chuk, Meredith K., Dombi, Eva, Goodspeed, Wendy, Goodwin, Anne, Kromplewski, Marie, Jayaprakash, Nalini, Marotti, Marcelo, Brown, Kathryn H., Wenrich, Barbara, Adamson, Peter C., Widemann, Brigitte C., Balis, Frank M.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2010
נושאים:
Original Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020690/
https://ncbi.nlm.nih.gov/pubmed/21060028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.9674
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים